FLT4 and neoplasm: The VEGFR‐3/VEGF‐C gradient has shown to enhance tumour cell proliferation, survival and migration in Kaposi sarcoma cells, malignant mesothelioma cells, leukaemia cells, lung adenocarcinoma, cervical and prostate cancer.40